{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Malignancy&page=5", "query": { "condition": "Hematologic Malignancy", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 7767, "total_pages": 777, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Malignancy&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Malignancy&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T10:07:51.843Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02743611", "title": "Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Uveal Melanoma" ], "interventions": [ { "name": "BPX-701", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2017-04-14", "completion_date": "2020-07-19", "has_results": true, "last_update_posted_date": "2023-10-05", "last_synced_at": "2026-10-20T10:07:51.843Z", "location_count": 3, "location_summary": "Denver, Colorado • Portland, Oregon • Nashville, Tennessee", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02743611" }, { "nct_id": "NCT04023071", "title": "FT516 in Subjects With Advanced Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "B-cell Lymphoma" ], "interventions": [ { "name": "FT516", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2019-10-04", "completion_date": "2023-10-23", "has_results": false, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-10-20T10:07:51.843Z", "location_count": 7, "location_summary": "Phoenix, Arizona • San Diego, California • Denver, Colorado + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04023071" }, { "nct_id": "NCT05430971", "title": "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)" ], "interventions": [], "intervention_types": [], "sponsor": "Immune Oncology Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 200, "start_date": "2022-07-01", "completion_date": "2032-07", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-20T10:07:51.843Z", "location_count": 3, "location_summary": "Miami, Florida • Tampa, Florida • Seattle, Washington", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05430971" }, { "nct_id": "NCT05015426", "title": "Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Gamma Delta T-Cell Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2022-03-21", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-20T10:07:51.843Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05015426" }, { "nct_id": "NCT02728050", "title": "Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Myeloid Leukemia", "de Novo Myelodysplastic Syndrome", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 84, "start_date": "2016-12-01", "completion_date": "2023-04-04", "has_results": true, "last_update_posted_date": "2023-07-05", "last_synced_at": "2026-10-20T10:07:51.843Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02728050" }, { "nct_id": "NCT00068718", "title": "Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma" ], "interventions": [ { "name": "Therapeutic Allogeneic Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "2003-05", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2020-01-31", "last_synced_at": "2026-10-20T10:07:51.843Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068718" }, { "nct_id": "NCT00081926", "title": "Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "Gleevec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2003-10", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2009-11-23", "last_synced_at": "2026-10-20T10:07:51.843Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081926" }, { "nct_id": "NCT02267278", "title": "Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Diseases" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Pracinostat", "type": "DRUG" }, { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2015-01-12", "completion_date": "2018-06-01", "has_results": true, "last_update_posted_date": "2019-06-12", "last_synced_at": "2026-10-20T10:07:51.843Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02267278" }, { "nct_id": "NCT04650178", "title": "Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COVID-19 Infection", "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Neuropathy" ], "interventions": [ { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 274, "start_date": "2020-05-26", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-10-20T10:07:51.843Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04650178" }, { "nct_id": "NCT00262925", "title": "Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "asparaginase", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2006-06", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2015-05-05", "last_synced_at": "2026-10-20T10:07:51.843Z", "location_count": 58, "location_summary": "Aurora, Illinois • Chicago, Illinois • Joliet, Illinois + 43 more", "locations": [ { "city": "Aurora", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00262925" } ] }